Kestra Medical Technologies, Ltd. (NASDAQ:KMTS – Get Free Report) CFO Vaseem Mahboob sold 34,809 shares of Kestra Medical Technologies stock in a transaction dated Tuesday, October 27th. The shares were sold at an average price of $30.04, for a total transaction of $1,045,662.36. Following the sale, the chief financial officer directly owned 60,609 shares in the company, valued at $1,820,694.36. The trade was a 36.48% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website.
Vaseem Mahboob also recently made the following trade(s):
- On Wednesday, October 28th, Vaseem Mahboob sold 39,903 shares of Kestra Medical Technologies stock. The shares were sold at an average price of $30.48, for a total transaction of $1,216,243.44.
- On Thursday, October 29th, Vaseem Mahboob sold 4,788 shares of Kestra Medical Technologies stock. The stock was sold at an average price of $30.60, for a total transaction of $146,512.80.
- On Friday, August 7th, Vaseem Mahboob sold 26,287 shares of Kestra Medical Technologies stock. The shares were sold at an average price of $25.88, for a total value of $680,307.56.
- On Tuesday, August 4th, Vaseem Mahboob sold 6,995 shares of Kestra Medical Technologies stock. The stock was sold at an average price of $24.68, for a total value of $172,636.60.
- On Monday, August 3rd, Vaseem Mahboob sold 5,391 shares of Kestra Medical Technologies stock. The stock was sold at an average price of $23.80, for a total transaction of $128,305.80.
- On Friday, July 31st, Vaseem Mahboob sold 8,817 shares of Kestra Medical Technologies stock. The shares were sold at an average price of $22.61, for a total transaction of $199,352.37.
Kestra Medical Technologies Stock Up 2.5%
KMTS traded up $0.74 during midday trading on Thursday, reaching $30.61. The company’s stock had a trading volume of 470,598 shares, compared to its average volume of 351,886. The company has a current ratio of 4.69, a quick ratio of 4.69 and a debt-to-equity ratio of 0.33. The firm has a market capitalization of $1.82 billion, a price-to-earnings ratio of -11.46 and a beta of 0.51. The stock’s 50-day moving average is $26.59 and its 200-day moving average is $23.76. Kestra Medical Technologies, Ltd. has a 1 year low of $17.34 and a 1 year high of $31.04.
Analysts Set New Price Targets
KMTS has been the subject of several recent analyst reports. Wall Street Zen cut shares of Kestra Medical Technologies from a “hold” rating to a “sell” rating in a report on Saturday, September 12th. JPMorgan Chase & Co. initiated coverage on shares of Kestra Medical Technologies in a research report on Monday, August 10th. They set an “overweight” rating and a $30.00 price target for the company. Weiss Ratings upgraded shares of Kestra Medical Technologies from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, September 16th. BTIG Research reaffirmed a “buy” rating and issued a $32.00 price objective on shares of Kestra Medical Technologies in a research report on Tuesday, September 15th. Finally, Wolfe Research set a $30.00 target price on Kestra Medical Technologies in a research note on Wednesday, July 15th. Five investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $29.00.
View Our Latest Analysis on Kestra Medical Technologies
Institutional Trading of Kestra Medical Technologies
A number of hedge funds have recently bought and sold shares of the company. Mirae Asset Global Investments Co. Ltd. purchased a new position in Kestra Medical Technologies in the third quarter worth about $353,000. Sterling Capital Management LLC increased its position in shares of Kestra Medical Technologies by 834.0% during the 3rd quarter. Sterling Capital Management LLC now owns 878 shares of the company’s stock valued at $25,000 after purchasing an additional 784 shares during the last quarter. Corient Private Wealth LP lifted its stake in shares of Kestra Medical Technologies by 284.2% in the 2nd quarter. Corient Private Wealth LP now owns 60,614 shares of the company’s stock worth $1,542,000 after purchasing an additional 44,839 shares during the period. California State Teachers Retirement System boosted its holdings in shares of Kestra Medical Technologies by 39.2% in the first quarter. California State Teachers Retirement System now owns 27,835 shares of the company’s stock worth $555,000 after buying an additional 7,844 shares during the last quarter. Finally, The Manufacturers Life Insurance Company boosted its holdings in shares of Kestra Medical Technologies by 6.6% in the first quarter. The Manufacturers Life Insurance Company now owns 92,515 shares of the company’s stock worth $1,844,000 after buying an additional 5,731 shares during the last quarter.
About Kestra Medical Technologies
Kestra Medical Technologies, Inc is a medical technology company focused on developing and commercializing wearable solutions for patients at risk of sudden cardiac arrest. Its primary product is the ASSURE wearable cardioverter defibrillator, a wearable device designed to continuously monitor a patient’s heart rhythm and deliver a therapeutic shock when clinically necessary.
The company’s platform combines cardiac monitoring, arrhythmia detection and defibrillation capabilities in a wearable system intended for use outside the hospital.
See Also
- Five stocks we like better than Kestra Medical Technologies
- Phillips 66 Posts Strong Earnings But the Stock Doesn’t Care
- NXP Semiconductors Falls After Strong Earnings—Is the Sell-Off Overdone?
- GE Vernova’s Reservations Are Turning Into Real Orders—But the Market Still Wants More.
- Where’s the Beef? Trian-Led Buyout Proposal Values Wendy’s at $1.4B, But Is It Enough?
Receive News & Ratings for Kestra Medical Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kestra Medical Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
